Salud financiera de hoja de balance de Innate Pharma
Salud financiera controles de criterios 4/6
Innate Pharma tiene un patrimonio de los accionistas total de €51.9M y una deuda total de €39.1M, lo que sitúa su ratio deuda-patrimonio en 75.3%. Sus activos y pasivos totales son €184.2M y €132.3M respectivamente.
Información clave
75.3%
Ratio deuda-patrimonio
€39.06m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | €92.46m |
| Patrimonio | €51.90m |
| Total pasivo | €132.29m |
| Activos totales | €184.19m |
Actualizaciones recientes sobre salud financiera
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Is Innate Pharma (EPA:IPH) Using Debt Sensibly?
May 04Recent updates
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)
May 13Is Innate Pharma (EPA:IPH) Using Debt Sensibly?
May 04A Look At Innate Pharma's (EPA:IPH) Share Price Returns
Feb 26Could The Innate Pharma S.A. (EPA:IPH) Ownership Structure Tell Us Something Useful?
Dec 24
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (€148.0M) de IPH superan a sus pasivos a corto plazo (€39.6M).
Pasivo a largo plazo: Los activos a corto plazo de IPH (€148.0M) superan a sus pasivos a largo plazo (€92.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: IPH tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de IPH ha crecido de 1.5% a 75.3% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IPH tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si IPH tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.